Azacitidine in myelodysplastic syndromes - A viewpoint

被引：0

作者：

Santini, V ^{[1
]}

机构：

[1] Univ Florence, Dept Haematol, Florence, Italy

来源：

DRUGS | 2005年 / 65卷 / 13期

关键词：

Myelodysplastic Syndrome; Acute Myeloid Leukaemia; Nucleoside Analogue; Require Blood Transfusion; Azacitidine;

D O I：

10.2165/00003495-200565130-00005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1790 / 1790

页数：1

共 3 条

[1] Response:: Myelodysplastic syndromes standardized response criteria:: further definition [J].

Cheson, BD ;

Bennett, JM ;

Kantarjian, H ;

Schiffer, CA ;

Nimer, SD ;

Löwenberg, B ;

Stone, RM ;

Mittelman, M ;

Sanz, GF ;

Wijermans, PW ;

Greenberg, PL .

BLOOD, 2001, 98 (06) :1985-1985

[2] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[3] Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B [J].

Silverman, LR ;

Demakos, EP ;

Peterson, BL ;

Kornblith, AB ;

Holland, JC ;

Odchimar-Reissig, R ;

Stone, RM ;

Nelson, D ;

Powell, BL ;

DeCastro, CM ;

Ellerton, J ;

Larson, RA ;

Schiffer, CA ;

Holland, JF .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2429-2440

← 1 →